Cynthia Aranow
YOU?
Author Swipe
View article: Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring
Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring Open
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper thres…
View article: Metabolic pathways within cTfh subsets and glucose-dependent activation of cTfh17 in SLE and healthy individuals
Metabolic pathways within cTfh subsets and glucose-dependent activation of cTfh17 in SLE and healthy individuals Open
Cellular metabolism plays a key role in T cell biology. Increased glycolysis and mitochondrial respiration have been identified in CD4+ helper T cells from both patients with systemic lupus erythematosus (SLE) and lupus mouse models. Inhib…
View article: Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus
Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus Open
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by an array of autoantibodies, in particular anti-nuclear antibodies (ANA). The disease is also hallmarked by an expansion of plasmablasts (PB) and hypergammaglobuli…
View article: INTERVAL-CENSORED OUTCOMES AND FLARE RISK AFTER HYDROXYCHLOROQUINE TAPERING/CESSATION: SENSITIVITY ANALYSES OF SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT DATA
INTERVAL-CENSORED OUTCOMES AND FLARE RISK AFTER HYDROXYCHLOROQUINE TAPERING/CESSATION: SENSITIVITY ANALYSES OF SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT DATA Open
O052 / #245 Topic: AS24 - SLE-Treatment ABSTRACT CONCURRENT SESSION 09: SLE THERAPY – REVISITING OLD DRUGS AND UNLOCKING HIDDEN POTENTIAL OF NEW MEDICATIONS 24-05-2025 10:40 AM - 11:40 AM Background/Purpose We previously evaluated hydroxyc…
View article: RHEUMATOLOGY DIAGNOSTICS UTILIZING ARTIFICIAL INTELLIGENCE FOR ANA PATTERN IDENTIFICATION AND TITRE QUANTIFICATION
RHEUMATOLOGY DIAGNOSTICS UTILIZING ARTIFICIAL INTELLIGENCE FOR ANA PATTERN IDENTIFICATION AND TITRE QUANTIFICATION Open
PT012 / #274 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes POSTER TOUR 03: RECENT ADVANCEMENTS IN SLE CLINICAL OUTCOMES AND THERAPY 23-05-2025 10:00 AM - 10:40 AM Background/Purpose Antinuclear antibody (ANA) immunofluorescence (…
View article: DAPIROLIZUMAB PEGOL DEMONSTRATED IMPROVEMENT IN QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: LUPUSQOL RESULTS FROM A PHASE 3 TRIAL
DAPIROLIZUMAB PEGOL DEMONSTRATED IMPROVEMENT IN QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: LUPUSQOL RESULTS FROM A PHASE 3 TRIAL Open
O011 / #377 Topic: AS19 - Patient-Reported Outcome Measures ABSTRACT CONCURRENT SESSION 01: FINDINGS FROM LUPUS CLINICAL TRIALS 22-05-2025 1:40 PM - 2:40 PM Background/Purpose Systemic lupus erythematosus (SLE) imposes significant disease …
View article: DIRECT AND INDIRECT COSTS ASSOCIATED WITH DAMAGE ACCRUAL: RESULTS FROM THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT
DIRECT AND INDIRECT COSTS ASSOCIATED WITH DAMAGE ACCRUAL: RESULTS FROM THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) INCEPTION COHORT Open
O030 / #400 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes ABSTRACT CONCURRENT SESSION 05: EMERGING INSIGHTS ON THE MANAGEMENT OF LUPUS MANIFESTATIONS AND COMORBIDITIES 23-05-2025 1:40 PM - 2:40 PM Background/Purpose We described …
View article: MACHINE LEARNING CAN IDENTIFY AN ANTINUCLEAR ANTIBODY PATTERN THAT MAY RULE OUT SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
MACHINE LEARNING CAN IDENTIFY AN ANTINUCLEAR ANTIBODY PATTERN THAT MAY RULE OUT SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES Open
O032 / #273 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes ABSTRACT CONCURRENT SESSION 05: EMERGING INSIGHTS ON THE MANAGEMENT OF LUPUS MANIFESTATIONS AND COMORBIDITIES 23-05-2025 1:40 PM - 2:40 PM Background/Purpose Antinuclear a…
View article: Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus
Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus Open
Objective The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti–doub…
View article: 2024 American College of Rheumatology (<scp>ACR</scp>) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
2024 American College of Rheumatology (<span>ACR</span>) Guideline for the Screening, Treatment, and Management of Lupus Nephritis Open
Objective The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis. Methods The Core Team developed clinical questions for screening, treatment, and management of lupus …
View article: A Provider‐Based Approach to Address Racial Disparities in Lupus Clinical Trial Participation
A Provider‐Based Approach to Address Racial Disparities in Lupus Clinical Trial Participation Open
OBJECTIVE: Substantial disparities exist in clinical trial participation, which is problematic in diseases such as lupus that disproportionately affect racial/ethnic minority populations. Our objective was to examine the effectiveness of a…
View article: Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set
Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set Open
The 25 candidate domains cover the important aspects of SLE and the 4 core areas of disease impact according to OMERACT framework. The 25 candidate domains constitute a feasible and manageable number of domains to proceed with to the core …
View article: IL-21-STAT3 axis negatively regulates LAIR1 expression in B cells
IL-21-STAT3 axis negatively regulates LAIR1 expression in B cells Open
LAIR1 is an inhibitory receptor broadly expressed on human immune cells, including B cells. LAIR1 has been shown to modulate BCR signaling, however, it is still unclear whether its suppressive activity can be a negative regulator for autor…
View article: Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study Open
Objectives To achieve consensus on domains of active disease for inclusion in a novel outcome measure for SLE randomised controlled trials (RCTs), the Treatment Response Measure for SLE (TRM-SLE). Methods Domains nominated by TRM-SLE Taskf…
View article: IFN-associated B cell hyperactivity is highly enriched in SLE patients harboring Sm/RNP antibodies
IFN-associated B cell hyperactivity is highly enriched in SLE patients harboring Sm/RNP antibodies Open
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by an array of autoantibodies, in particular anti-nuclear antibodies (ANA). The disease is also hallmarked by an expansion of plasmablasts (PB) in peripheral blood. …
View article: Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus
Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus Open
BACKGROUND: Cranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia a…
View article: A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach Open
OBJECTIVE: To study bidirectional change and predictors of change in estimated glomerular filtration rate (GFR) and proteinuria in lupus nephritis (LN) using a multistate modeling approach. METHODS: Patients in the Systemic Lupus Internati…
View article: Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort
Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort Open
OBJECTIVE: To describe the frequency of myocardial infarction (MI) prior to the diagnosis of systemic lupus erythematosus (SLE) and within the first 2 years of follow-up. METHODS: The systemic lupus international collaborating clinics (SLI…
View article: Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases
Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases Open
To study responses to COVID-19 vaccine in autoimmune patients
View article: 1105 Persistent neuroinflammation in SLE
1105 Persistent neuroinflammation in SLE Open
To understand how neuroinflammation is sustained in the absence of systemic inflammation we have studied a mouse model of neuropsychiatric lupus (NPSLE) which is triggered by the penetration of neurotoxic antibodies into the hippocampus. …
View article: Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus
Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus Open
Background Cranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia an…
View article: P31 A novel disease endotype in SLE characterized by B cell hyperactivity, Sm/RNP reactivity and higher disease activity
P31 A novel disease endotype in SLE characterized by B cell hyperactivity, Sm/RNP reactivity and higher disease activity Open
Objective Uncontrolled plasma cell (PC) expansion and hypergammaglobulinemia are hallmarks of B cell hyperactivity in the autoimmune disease Systemic Lupus erythematosus (SLE). While the presence of autoantibodies, in particular anti-nucle…
View article: Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the <scp>SLICC</scp> Inception Cohort
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the <span>SLICC</span> Inception Cohort Open
Objective The goals of this study were to assess the associations of severe nonadherence to hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality r…
View article: LO-024 Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort
LO-024 Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort Open
Background Hydroxychloroquine is one of the major treatment of SLE, but its effectiveness is impaired by non-adherence, reported to range from 3% to 85% in SLE patients. Our objective was to assess the associations of severe non-adherence …
View article: Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE Open
Objective There is a lack of data on the use of telemedicine (TM) in SLE. SLE outcome measures remain complex, and clinicians and clinical trialists have raised concerns about the accuracy of virtual disease activity measures. This study e…
View article: LO-033 Towards a novel clinical outcome assessment for systemic lupus erythematosus trials – first outcomes of an international consensus process
LO-033 Towards a novel clinical outcome assessment for systemic lupus erythematosus trials – first outcomes of an international consensus process Open
Background Measurement of treatment effects in systemic lupus erythematosus (SLE) randomised controlled trials (RCTs) remains challenging. Current RCT endpoints are not based on contemporary outcome assessment methodology. We report the cu…